<?xml version="1.0" encoding="UTF-8"?>
<p>The NPV antibody prevalence rate in humans (13.9%) is comparable to that of GFV, which is 17%–60% in Sudan, 3%–10% in Egypt, and 3% in Nigeria (
 <xref rid="R7" ref-type="bibr">
  <italic>7</italic>
 </xref>). KARV antibody prevalence is 1%–11% in Sudan, 2% in Egypt, and 1%–62% in regions of Iran and Russia (
 <xref rid="R7" ref-type="bibr">
  <italic>7</italic>
 </xref>). Human serum samples from northern Kenya have been tested and yielded no antibodies against GFV or KARV, which matches our results (
 <xref rid="R7" ref-type="bibr">
  <italic>7</italic>
 </xref>). 
</p>
